1. Home
  2. BTO vs CSTL Comparison

BTO vs CSTL Comparison

Compare BTO & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Hancock Financial Opportunities Fund

BTO

John Hancock Financial Opportunities Fund

HOLD

Current Price

$35.27

Market Cap

673.2M

Sector

Finance

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$38.83

Market Cap

661.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTO
CSTL
Founded
1994
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
673.2M
661.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
BTO
CSTL
Price
$35.27
$38.83
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$38.67
AVG Volume (30 Days)
54.2K
439.7K
Earning Date
01-01-0001
11-03-2025
Dividend Yield
9.13%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$343,530,000.00
Revenue This Year
N/A
$1.69
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
10.15
52 Week Low
$22.95
$14.59
52 Week High
$32.81
$40.61

Technical Indicators

Market Signals
Indicator
BTO
CSTL
Relative Strength Index (RSI) 63.04 71.92
Support Level $34.09 $38.69
Resistance Level $34.75 $40.54
Average True Range (ATR) 0.72 1.58
MACD 0.31 -0.18
Stochastic Oscillator 93.17 75.59

Price Performance

Historical Comparison
BTO
CSTL

About BTO John Hancock Financial Opportunities Fund

John Hancock Financial Opportunities Fund is the United States based closed-end, diversified management investment company. Its investment objective is to provide a high level of total return consisting of long-term capital appreciation and current income. The company invests in banks, capital markets, Insurance, Mortage Real Estate Investment trust, Health Care REITs, Diversified REITs, Office REITs.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Share on Social Networks: